Participants are being recruited for a Phase II clinical study of capecitabine and temozolomide (CAPTEM) for neuroendocrine cancer patients with progressive, differentiated, metastatic neuroendocrine tumors (NETs). Patients with carcinoid, pancreatic neuroendocrine tumors, pheochromocytomas, MEN1 and MEN2, and gastrinomas are among those eligible for this study in New York City. The principal investigator for the study is Robert L. Fine, MD at Columbia University.
According to carcinoid/NET specialist Richard R.P. Warner, MD, Medical Director of the Carcinoid Cancer Foundation, Professor of Medicine and Director of the Center for Carcinoid/NETs at the Mount Sinai Hospital, this chemotherapy combination has been in use for approximately 7 years and is available on the market for physicians to use on a off-label basis for NET patients. Dr. Warner says he has “observed a very promising response to this regime in carcinoid and related NETs patients.” He encourages suitable patients to enter the clinical trial.